Merck Reports Results from the P-III (ZENITH) Study of Winrevair (Sotatercept-csrk) for Pulmonary Arterial Hypertension
Shots:
- Merck has reported topline data from P-III (ZENITH) trial assessing Winrevair plus background PAH therapy vs matching PBO in high-risk PAH (WHO FC III/IV) patients (n=172)
- Study achieved its 1EP of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥24hrs.), with balanced AEs b/w the groups. Based on these outcomes, an independent committee recommended stopping the trial early, offering participants Winrevair in the SOTERIA open-label extension trial
- Data will be highlighted at future conferences and will be shared with regulatory authorities
Ref: Merck | Image: Merck
Related News:- Exelixis and Merck Join Forces to Develop Zanzalintinib for Head and Neck Cancer and Renal Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
